Strategies for the enhancement of IL-21 mediated antitumor activity in solid tumors

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Solid tumors represent a significant global health burden, driving the need for advanced therapeutic strategies.
• Immunotherapy, particularly targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1), offers new avenues for treating advanced cancers.
• Interleukin-21 (IL-21), a cytokine activating the JAK/STAT pathway, has demonstrated antitumor potential in clinical trials, but its efficacy is limited by side effects and pharmacokinetic properties.

Purpose of the Study:

• To review the mechanisms of IL-21 action in common high-incidence solid tumors.
• To explore enhanced strategies for IL-21-based immunotherapy in solid tumors.
• To provide a theoretical framework for developing targeted IL-21 treatment approaches.

Main Methods:

• Literature review of IL-21's role in cancer immunology.
• Analysis of current clinical trial data on recombinant IL-21.
• Exploration of combination therapies involving IL-21 and other cancer treatments.

Main Results:

• Recombinant IL-21 exhibits promising antitumor activity and manageable toxicity in clinical settings.
• Challenges such as side effects, off-target effects, and short half-life impede IL-21's therapeutic effectiveness.
• Combination strategies integrating IL-21 with immune checkpoint inhibitors, cytokines, vaccines, or radiotherapy are crucial for enhancing response rates.

Conclusions:

• IL-21 holds significant potential as an immunotherapeutic agent for solid tumors.
• Overcoming IL-21's limitations through combination therapies is essential for improving treatment efficacy.
• Further research into optimized IL-21 strategies can lead to improved survival for cancer patients.